# Medroxyprogesterone Acetate vs LNG-IUS in Early-stage Endometrioid Carcinoma and Atypical Hyperplasia Patients

> **NCT05565573** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Hua Li** · enrollment: 148 (estimated)

## Conditions studied

- Fertility Sparing

## Interventions

- **DRUG:** Medroxyprogesterone Acetate 500 MG Oral Tablet
- **DEVICE:** Levonorgestrel-Releasing Intrauterine System

## Key facts

- **NCT ID:** NCT05565573
- **Lead sponsor:** Hua Li
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-11-01
- **Primary completion:** 2024-07-01
- **Final completion:** 2025-11-01
- **Target enrollment:** 148 (ESTIMATED)
- **Last updated:** 2022-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05565573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05565573, "Medroxyprogesterone Acetate vs LNG-IUS in Early-stage Endometrioid Carcinoma and Atypical Hyperplasia Patients". Retrieved via AI Analytics 2026-08-24 from https://api.ai-analytics.org/clinical/NCT05565573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*